36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Benet 75 mg Tablets
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Risedronic acid (Primary)
- Indications Osteoporosis; Vertebral fracture
- Focus Therapeutic Use
- Sponsors Takeda
- 28 Sep 2017 Planned End Date changed from 1 Apr 2018 to 30 Apr 2018.
- 28 Sep 2017 Planned primary completion date changed from 1 Apr 2018 to 30 Apr 2018.
- 15 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.